Dupilumab in a patient with severe asthma and glucocorticoid hypersensitivity: a case report
| Autor: | Hiroshi Handa, Hajime Tsuruoka, Kohei Kinoshita, Masamichi Mineshita |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Journal of International Medical Research, Vol 51 (2023) |
| Druh dokumentu: | article |
| ISSN: | 1473-2300 03000605 |
| DOI: | 10.1177/03000605231193922 |
| Popis: | Recently, several biologics have been approved for the treatment of severe asthma. Dupilumab, a biologic used to treat severe asthma, is a monoclonal antibody targeting interleukin-4 and interleukin-13. In the present case, inhaled corticosteroid-induced glucocorticoid hypersensitivity was suspected, and the administration of omalizumab and mepolizumab had no beneficial effects. Subsequently, we switched to dupilumab therapy, which produced better effectiveness. Therefore, when a biologic agent proves ineffective, changing to another suitable biologic agent should be considered. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|